Skip to main content
. 2005 Apr 6;7(3):119–130. doi: 10.1186/bcr1023

Table 4.

Clinical efficacy of fulvestrant after progression on prior endocrine therapy with AIs

Study [ref.] Treatment (setting) Prior systemic treatments Number of Clinical benefita (%)
Perey et al. [93] Fulvestrant (third line) Include tamoxifen and AIs 67 28
Ingle et al. [92] Fulvestrant (second and third line) Prior nonsteroidal AIs, and tamoxifen in 79% of patients 77 29
Petruzelka and Zimovjanova [94] Fulvestrant (second to fifth line) Include nonsteroidal AIs, adjuvant tamoxifen, and goserelin formestane 44 52
Franco et al. [91] Fulvestrant (mean prior endocrine therapies = 3.4) Include nonsteroidal AIs, tamoxifen, megestrol acetate, exemestane, and chemotherapy 42 19
Steger et al. [95] Fulvestrant (second to fifth line) Include nonsteroidal AIs, tamoxifen, exemestane, goserelin, and formestane 88 57

Phase II clinical trials with fulvestrant following disease progression on prior endocrine therapy with aromatase inhibitors are summarized. aClinical benefit included patients who had a complete response, partial response, or stable disease for 24 weeks or longer. AI, aromatase inhibitor.